Guangzhou Bioprocess Academy opens in Guangzhou, China
GUANGZHOU, CHINA and DUBLIN, IRELAND, September 28th 2020 –Guangzhou International Bio Island opens a training centre for biologics manufacturing in Guangzhou, China in partnership with Ireland’s National Institute for Bioprocessing Research and Training (NIBRT).
The opening of the Guangzhou Bioprocess Academy (GBA) was announced today at Bio Island, Guangzhou, China. The new training facility will provide hands-on practical training to support the rapid growth of biologics manufacturing in China. The facility has state-of-the-art single use equipment to ensure Chinese clients receive best-in-class workforce development programmes. The courses at GBA will be based on the world leading NIBRT curriculum. With the rapid development of the biopharma industry around the world, GBA will provide the highest quality biopharmaceutical training to help provide the biopharma talent required in China. GBA is a member of Guangzhou Hi-tech Investment Group (GHIC). Mr. Xu Hongsheng, Chairman of GHIC, says, “We are very pleased to join hands with NIBRT and Cytiva to develop the training centre to become a training centre of global bio-manufacturing technology, and to promote the development of China’s biopharmaceutical industry by cultivating biomanufacturing technology talents with in-depth perspectives of China’s industry and global horizon.”
GBA is developed in partnership with NIBRT whose industry leading curriculum will be available at the centre. GBA will now join NIBRT’s Global Partner Programme which also includes the Jefferson Institute for Bioprocessing in Philadelphia, USA and the Biologics Innovation Facility in Sydney, Australia. NIBRT CEO, Darrin Morrissey, welcomed the partnership with GBA commenting “As the demand for the highly skilled biologics workforce continues to increase across the globe, we are delighted to partner with GBA to ensure that the NIBRT curriculum will now be available to clients in China. We look forward to GBA joining our Global Partner Programme and to strengthening the relationship with the Chinese biologics industry. ”
The investment in GBA has been supported by Cytiva, a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Cytiva will closely work with NIBRT to deliver the education courses, while providing single-use equipment and dedicated Fast Trak course trainers.
Lihua Yu, General Manager of Cytiva China, remarked, “Together with GBA and NIBRT, we will continually transform Cytiva’s experiences and expertise into biotechnology R&D, manufacturing and management know-how to drive the professional training development for China local talents. It’s one solid part of our ‘In China, For China’ strategy which aims to bring speed, efficiency and capacity to the biopharmaceutical industry to benefit patients in China and around the world.”
Mr. Wei Zeng, Chairman of Guangzhou Bioprocess Academy; Ms. Yu Xin, CEO of Guangzhou Hi-tech Investment Group; Mr. Huang Weijian, Deputy Director of GDD Investment Promotion Bureau; Ms. He Lulu, Vice Governor of GDD; Ms. Therese Healy, Charge d’Affaires, Embassy of Ireland; Ms. Yu Lihua, CEO of Cytiva Great China, Mr. Jevery Zhang, Director of IDA China.